Table 3.
Response of patients with measurable disease
| All (n = 71) | Group A (n = 43) | Group B (n = 28) | |
|---|---|---|---|
| PR | 12 (17%) | 6 (14%) | 6 (21%) |
| SD | 52 (73%) | 31 (72%) | 21 (75%) |
| PD | 4 (6%) | 3 (7%) | 1 (4%) |
| Unknown | 3 (4%) | 3 (7%) | 0 (0%) |
| ORR | 17% | 14% | 21% |
| P value (ORR) | – | 0.494 | |
| χ 2 | – | 0.468 | |
| DCR | 90% | 86% | 96% |
| P value (DCR) | – | 0.498 | |
| χ 2 | – | 0.459 | |
Group A, CAPEOX + Cetuximab; Group B, FOLFOX + Cetuximab.
DCR, disease control rate; ORR, objective response rate; PD, progression disease; PR, partial response; SD, stable disease.